- Belmora LLC
Baltimore District Office
July 19, 2017
Reference: CMS# 521015
Ms. Jamie Belcastro, President and Founder
2231 Crystal Drive, Unit 100
Arlington, VA 22202
Dear Ms. Belcastro:
On July 19, 2017, The Food and Drug Administration completed an evaluation of your firm’s corrective actions in response to our Warning Letter (#521015), dated June 8, 2017. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of the corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
CDR Rochelle B. Young, RPh, MSA
Capote Law Firm